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Antenatal corticosteroids: a reappraisal of the drug
formulation and dose
Alan H. Jobe1,2, Matthew Kemp1,3,4, Augusto Schmidt5, Tsukasa Takahashi1,3, John Newnham1 and Mark Milad6
We review the history of antenatal corticosteroid therapy (ACS) and present recent experimental data to demonstrate that this, one
of the pillars of perinatal care, has been inadequately evaluated to minimize fetal exposure to these powerful medications. There
have been concerns since 1972 that fetal exposures to ACS convey risk. However, this developmental modulator, with its multiple
widespread biologic effects, has not been evaluated for drug choice, dose, or duration of treatment, despite over 30 randomized
trials. The treatment used in the United States is two intramuscular doses of a mixture of 6 mg betamethasone phosphate (Beta P)
and 6mg betamethasone acetate (Beta Ac). To optimize outcomes with ACS, the goal should be to minimize fetal drug exposure.
We have determined that the minimum exposure needed for fetal lung maturation in sheep, monkeys, and humans (based on
published cord blood corticosteroid concentrations) is about 1 ng/ml for a 48-h continuous exposure, far lower than the
concentration reached by the current dosing. Because the slowly released Beta Ac results in prolonged fetal exposure, a drug
containing Beta Ac is not ideal for ACS use.
Pediatric Research (2021) 89:318–325; https://doi.org/10.1038/s41390-020-01249-w
IMPACT:
● Using sheep and monkey models, we have defined the minimum corticosteroid exposure for a fetal lung maturation.
● These results should generate new clinical trials of antenatal corticosteroids (ACS) at much lower fetal exposures to ACS,
possibly given orally, with fewer risks for the fetus.
CURRENT TREATMENTS WITH ANTENATAL CORTICOSTEROIDS
(ACS)
ACS treatments are standard treatments for all women at risk of
preterm delivery worldwide as recommended by obstetric
practice guidelines1 and the World Health Organization (WHO)
as the most effective way to decrease preterm infant deaths.2 As
such, one may ask why should we be re-evaluating that
treatment? As stated in 2015 in the Journal of the American
Medical Association, relative to the Declaration of Helsinki:
Even the best proven interventions must be evaluated
continually through research for their safety, effectiveness,
efficacy, accessibility and quality.3
ACS is a unique therapy for a very high-risk population (the
preterm fetus) developed initially by Liggins and Howie in 1972 4
based on results from sheep models from the 1960s.5 It is
surprising that the initial treatment of two 12mg doses of a 1:1
mixture of betamethasone phosphate (Beta P) and betametha-
sone acetate (Beta Ac) proposed and tested by Liggins in his 1972
randomized controlled trial remains the standard therapy in the
US, Europe, and Australia.6 Liggins5 selected the mixture because
the slowly released Beta Ac would accomplish longer fetal
exposures. However, the need for a prolonged fetal exposure
was never verified as essential for the clinical response until we
tested the Beta Ac component of the two-drug combination used
in clinical practice in sheep and monkey models recently.7–16 Most
of the repeat treatment regimens that are used worldwide have
not been tested for safety and efficacy.
The current WHO recommended treatment is four doses of 6
mg dexamethasone phosphate (Dex P) (total dose 24 mg)
because of low costs and widespread availability.2 A recent
international multicenter randomized controlled trial (RCT)
compared two doses of 12 mg Beta P and Beta Ac against two
doses of 12 mg Dex P spaced by 24 h had equivalent outcomes,
demonstrating that the drugs are interchangeable for the ACS
indication.17 In a recent Cochrane review of ACS, other
treatments that have been tested clinically were reviewed.18
Multiple aspects of ACS dosing have not been systematically
evaluated, including which drug, what treatment interval, which
dose, and which drug for which treatment interval. The basic
pharmacokinetics (PK) of the major drugs used for ACS have
been minimally studied in pregnant women and their fetuses.19
The PK and pharmacodynamics (PD) are complex as a drug is
given to the pregnant woman to treat her fetus. This creates
multiple variables of maternal PK, placental drug transfer and
metabolism, blood levels in the fetus and fetal metabolism, as
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well as drug response levels for the multiple PD effects in the
human fetus, which can only be evaluated after delivery using
clinical outcomes and drug levels in cord blood (Fig. 1). For
example, we do not know if the same exposure will benefit lung
maturation, death, and intraventricular hemorrhage (IVH) or
does each benefit require a different dose and period of
exposure. We will use only lung maturation (lung compliance
and gas exchange after preterm delivery) as the measurement
for corticosteroid PD effect for this review as there is more
information from RCTs about lung maturation than other
effects.
CONCERNS ABOUT CURRENT DOSING
1. The standard dose of 24mg Dex P or Beta P+ Beta Ac is a
very large dose of corticosteroids based on common
medical usage.20
2. Corticosteroids are potent modulators of development and
there are indications that there may be effects on human
populations from ACS including birth weight21 and neuro-
development.22,23 Risks are proportional to dose.24
3. Larger numbers of fetuses are being exposed beyond the
initial indication of 24–34 weeks gestational age with the
anticipation of imminent preterm deliveries for late preterm
deliveries,25 very preterm, periviable deliveries, and elective
C-sections.26
4. There is no information that ACS actually benefit pregnan-
cies in low and middle income countries (LMIC) where most
of the premature deaths occur.27 In fact, newborn mortality
increased with ACS use in environments with marginal
medical care for the women and the infant following
preterm delivery at 24–34 weeks.28
5. Treatments that contain Beta Ac result in very long fetal
exposures if the fetus does not deliver within 4–7 days of
the efficacy interval for minimal benefit.2
6. The many meta-analyses of ACS simply evaluate small
variances of the Liggins dosing. The large number of trials
have hidden the fact that no dose ranging information is
available for ACS.
7. There has been no input from regulatory agencies for ACS
therapy and it is not FDA approved. Many clinical research
resources were used that did not add new information.29
The meta-analyses are extensive and simply represent small
variances of the Liggins dosing with no attempt to do formal dose
range testing to define a minimal dose to limit fetal exposure and
complications.6,18,30,31 As all the dosing is high, the trials
comparing drugs are not helpful for minimizing dosing and
defining minimal exposures. From our perspective, the number of
trials and total number of patients enrolled with consistent
outcomes has hidden the fact that no dose ranging information is
available for ACS to evaluate effectiveness after treatment,
perhaps the most tested intervention in perinatal medicine.
PK IN NONPREGNANT WOMEN
Beta P and Dex P are rapidly dephosphorylated to betamethasone
or dexamethasone within minutes32 to yield the nonphosphory-
lated betamethasone or dexamethasone. The ratio of maternal
Beta to fetal Beta is about 0.4 using cord blood at the time of
delivery if delivery is within 6 days of treatment.33 Therefore,
shortly after a maternal 12mg dose, maternal Beta levels should
be about 100 ng/ml from the 6mg Beta P component of the
drug34 (Fig. 2). This is a high level relative to the much lower level
that is needed for lung maturation, as we will develop below.
We recently reported a large PK/PD study in 48 normal weight
reproductive age nonpregnant women from Bangalore, India who
received one 6mg dose of Beta P or Dex P PO or IM (Fig. 2).34 With
samples from 12 or 24 women for each treatment of either 6 mg
of Beta P+ Beta Ac, 6 mg of Beta P, or 6 mg of Dex P, the
absorption and clearance curves were very consistent (Fig. 2a).
Both Beta P and Dex P were rapidly absorbed (1.5 h oral, 3 h IM)
with comparable maximal concentrations (65–95 ng/ml) for IM or
oral dosing. In contrast, the maximal concentration for the IM Beta
P+ Beta Ac mixture was about 50% of the level for the
phosphorylated drug because the slowly absorbed Beta Ac did
not contribute to the initial blood levels at early times. The plasma
half-life of dexamethasone (5.2 h) was cleared twice as fast as for
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Fig. 1 Sketch of fetal blood levels estimated from cord blood.45 These curves represent predicted fetal plasma after maternal treatments
with the 3mg betamethasone phosphate (Beta P) plus 3 mg betamethasone acetate (Beta Ac) mixture given 24 h apart (red curve), 3 mg
dexamethasone phosphate (Dex P) given every 12 h (orange curve), and 3mg Beta Ac component (blue curve) based on measurements in a
sheep model with the characteristics of drug levels that we will discuss. The light gray area on the figure is our estimate of a good target for
fetal plasma levels for lung maturation. Issues for dosing are: 1. The range for minimal dose for fetal lung response. 2. Need for high peak
exposure. 3. Nature of exposure—duration and continuous for a durable response. Redrawn from Ballard and Ballard.45
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treated the women with 1 drug and after a washout period of
9 days after the first drug, we administered a second drug (Dex P,
PO, or IM) and the corticosteroid concentrations were again
measured to 96 h. At 9 days after Beta P+ Beta Ac, the
betamethasone concentrations was 0.36 ± 0.88 ng/ml. This would
translate to 1.36 ng/ml for a 12mg exposure to Beta Ac for the
clinical treatment which contains 12mg Beta Ac. Consistent with
an NICHD data set of women treated with 12mg Beta P+ Beta Ac
had maternal plasma levels of about 3 ng/ml at 6.5 days after the
second 12mg drug dose.33 A caution of interpretation: blood
concentrations are likely to be different in pregnant women
because of multiple pregnancy-related metabolic changes, but
there is not good data of high resolution in pregnancy.33
Fetal cord blood levels 6.5 days after the last treatment were
about 2 ng/ml.33 In a recent second report of betamethasone
concentrations after the two-dose clinical treatment,35 cord blood
betamethasone concentrations after maternal treatment mea-
sured in cord blood found maternal concentrations of about 4 ng/
ml at 3–4 days after the second dose and cord blood
concentrations also at over 4 ng/ml.35 The maternal/fetal blood
concentration ratio was reported to be about 0.4,29,35 but that
ratio changes clearly. Maternal and cord blood levels were
comparable in maternal plasma and cord plasma at a later time
after treatment by 3–4 days,33,35 probably because the beta-
methasone levels had reached an equilibrium between maternal
and fetal compartments.
Although we are focusing on lung maturation effects,
corticosteroids have pleotropic effects on the mother and fetus.
From our Bangalore study of PK in nonpregnant healthy women,
we also measured PD effects on glucose and cortisol and other
white blood cells—all were significantly altered by 6mg doses of
Beta P or Dex P (Fig. 2b, c).34
Baseline plasma glucose values for the 24 h before corticoster-
oid treatment were very similar across the five treatment groups
(Fig. 2a).34 Blood glucose increased similarly in the treatment
groups from the fasting baseline of about 100 mg/dl to about 200
mg/dl in association with lunch after an overnight fast. Thus, a
single dose of 6 mg Beta or Dex had a large effect on maternal
plasma glucose for 24 h with residual effects into day 2, when, in
clinical practice, pregnant women would be receiving a second
dose, which would further alter blood sugar.
The average AM plasma cortisol was about 70 ng/ml with a
normal diurnal rhythm prior to treatment (Fig. 2c).34 The five-drug
treatments caused rapid and similar decreased cortisol to a
minimal concentration of about 4 ng/ml with similar periods of
suppression for about 60 h for oral and IM Dex P. Cortisol was
suppressed for about 72 h for the oral or IM Beta P. The Beta P+
Beta Ac caused a prolonged suppression for more than 4 days.34
Assuming routine clinical treatment with two doses of Beta Ac+
Beta P, the adrenal suppression could be much longer, so that
second course of treatment may keep the pregnant woman
immunosuppressed for several weeks.
Therefore the PK measurements give us two valuable pieces
of information: (1) Dex P has about a twofold shorter half-life
compared to Beta P, which will influence the number and
interval of doses used for modeling dosing for both Dex P and
Beta P (Fig. 1).36 (2) The information suggests the potential to
decrease risks by using lower doses that Beta P+ Beta Ac poses
for neurodevelopmental injury37 is the persistence of beta-
methasone in cord blood for 1 week after treatment.37 The
combination drug is a poor choice for a fetal therapy as the
standard treatment is exposing the fetus to measurable blood
concentrations for at least two weeks. This observation results in
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Fig. 2 Pharmacokinetic and pharmacodynamics studies of corticosteroids in nonpregnant, reproductive age women. a Pharmacokinetic
measurements of betamethasone phosphate (Beta Phos—6mg) given orally or IM, dexamethasone (Dex Phos—6mg) given orally or IM dose,
or 6mg of the 1:1 mixture of Beta Phos (3 mg) plus Beta Acetate (Beta Ac, 3 mg) given IM to healthy Indian women with blood measurements
over 96 h and after 9 days from the initial dose (redrawn from ref. 34). Beta from the Beta P plus Beta Ac had a slow clearance with blood levels
measurable 9 days after the initial dose and with no further apparent clearance between 9 and 13 days from the Beta Ac component. b Effects
of ACS on plasma glucose. A single dose of 6mg dexamethasone P or the 1:1 mixture of 3 mg Beta P+ 3mg of Beta Ac increased post-
prandial blood glucose. All PO and IM treatments had comparable effects on blood sugar (redrawn from ref. 34). c Effects of single ACS doses
on cortisol. A single dose of 6mg dexamethasone P or the 1:1 mixture of 3mg Beta P+ 3mg of Beta Ac suppressed cortisol, but the Beta
P plus Beta Ac treated group had longer suppression of cortisol to more than 4 days (redrawn from ref. 34).
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have been using the wrong drug for 48 years. The IM Beta Ac
forms a delayed release Beta source after IM injection that
results in very slow drug release.
The use of a drug with Beta Ac also makes no sense in terms of
the large literature and discussions of repeated courses of ACS. All
the studies of repeated courses of ACS used Beta P+ Beta Ac for
the initial treatment.23 The standard treatment has a treatment
effect that probably lasts 2 weeks already; thus, there should be
no need for repeated treatments. The benefits of repeated
treatments are quite modest in a recent individual participant
meta-analysis,23 which does not surprise us in light of the
pharmacokinetic data. A complete unknown is the fate of
maternally derived Dex or Beta in the fetus after delivery.
WHAT MINIMAL BETA EXPOSURE IS REQUIRED FOR LUNG
MATURATION IN SHEEP?
In 2007, we published an experiment where pregnant ewes
received one dose of 0.5 mg/kg Beta P or a single dose of 0.25 mg/
kg Beta P or one or two doses maternal IM Beta P+ Beta Ac
mixture (0.5 mg/kg).14 We found that one dose of 0.5 mg/kg IM
Beta P did not cause lung maturation but the Beta P+ Beta Ac
combination did cause lung maturation. All treatments would
have caused high initial maternal plasma levels34 for a treatment
to delivery interval of 2 days. Despite these very high doses of the
Beta P, there was no lung maturation. Therefore, the high peak
maternal blood concentrations that occur soon after treatment are
not sufficient by themselves to cause the lung maturation
response.
In 2009,15 we made extensive PK and PD measurements for the
drugs used for ACS with support from the Bill & Melinda Gates
Foundation22 (Fig. 3). Using the same sheep model as in 2007, we
treated pregnant ewes with 0.5, 0.25, or 0.125 mg/kg Beta Ac only
in comparison to one or two doses of Beta Ac+ Beta P—the
clinical combination drug. In this experiment we tested Beta Ac at
a lower dose and did more precise maternal and fetal blood level
measurements (Fig. 3). Two days after the initial treatment, a
single dose of 0.125 mg/kg of Beta Ac was as effective in inducing
lung maturation as two doses of 0.25 mg/kg Beta P+ Beta Ac. So
in sheep we estimate a minimal fetal exposure to Beta to be about
2 ng/ml based on the PK results for Beta Ac (Fig. 3a). The clinical
dose is 24mg. If we assume that the average women in preterm
labor weighs 70 kg, then her corticosteroid exposure is 0.34 mg/
kg. In clinical practice, ACS corticosteroid dose has not been
adjusted for maternal weight or body mass index,25,38 and clinical
outcomes have been insensitive to maternal weight or multiple
fetuses —probably because the dose treatments are already so
high.
BETA P INFUSIONS TO TEST MINIMUM EXPOSURE AND
DURABILITY OF LUNG MATURATION—SHEEP
A more revealing approach was evaluated in sheep using
maternal infusions of Beta P to achieve target blood levels of
betamethasone in the fetus (Fig. 4a).7 We used loading doses and
constant maternal infusions of Beta P to target stable fetal blood
levels of 20, 10, or 2 ng/ml for 12 h. This PK study demonstrated
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Fig. 3 Testing for minimal ACS dose for fetal lung maturation in sheep. aMaternal and fetal plasma levels of betamethasone for treatments
with 0.125mg/kg Beta Ac maternal IM. Area under the curve (AUC0–24 h) is 443 ng/ml h for Beta in the ewe and 56 ng/ml h in the fetus. The
fetal levels stay above 1 ng/ml for 24 h. Redrawn from ref. 16 b Maternal and fetal drug levels after 0.125mg/kg Beta P. AUC0–24 in ewes were
557 and 79 ng/ml h in fetus. Redrawn from ref. 16 The fetal levels remain above 1 ng/ml for only 8 h despite the very high plasma levels in the
ewes. c Pressure–volume curves after preterm delivery and ventilation measured 2 days after a single treatment, showing similar
improvements of the low-dose Beta Ac and the clinical dosing. d The composite gas exchange variable, Ventilation Efficiency Index (VEI)
which incorporates tidal volume/kg, peak ventilation pressure, PaCO2, and ventilation rate for the clinical dosing and Beta Ac
component alone showing similar improvements of the VEI with low-dose Beta Ac and the clinical dosing. Redrawn from ref. 16. *Different
than control p < 0.05.
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achieved for 12 h for the 20 ng/ml group with rapid clearance
from the fetal circulation after 12 h (Fig. 4a). Figure 4 has a gray
zone from 1 to 4 ng/ml fetal betamethasone because fetal
betamethasone levels in that range for 24 h were effective for
lung maturation using Beta Ac in sheep.16
To evaluate lung function, separate groups of pregnant ewes
were given the same targeted infusions and delivered 48 h after
the initiation of the infusions and ventilated for 30min. The values
at 30 min for the Ventilation Efficacy Index demonstrated that the
20 ng/ml exposure induced lung maturation, while the 10 ng/ml
had inconsistent results (Fig. 4b) and the 2 ng/ml target was not
effective (Fig. 4). Despite the 10 ng/ml plasma target infusion
greatly exceeding the exposure from 0.125 mg/kg Beta Ac for 12 h,
there was minimal lung maturation suggesting that a 12 h
exposure was insufficient to induce lung maturation. The static
lung gas volumes at necropsy gave the same pattern of results.
However, subsequent clearances were sufficiently slow to keep
Beta levels above 1 ng/ml for about 24 h for those animals in the
20 ng/ml target group (Fig. 4a) and lung maturation occurred in
the animals. The 2 ng/ml target was below 1 ng/ml by 16 h and no
maturation occurred. Based on the result with the 10 ng/ml group
and the efficacy of 0.125mg/kg Beta Ac, a treatment interval of
<24 h is not sufficient to induce lung maturation.
We also tested the durability of 1 vs 2 doses of Beta Ac+ Beta
P—the clinical dose in sheep. One dose induced lung maturation
at 24 h and 48 h (Fig. 4c), but that effect was lost by 7 days
(Fig. 4d). In contrast, two doses at a 24-h interval had a durable
effect to 7 days with some residual effects at a 10-day treatment
to delivery interval.9 These PK data were generated with the
maternal infusions of Beta P and maternal IM Beta P+ Beta Ac.
The fetal exposure profile for optimal responses at low total dose
should be generally applicable for any route of treatment or
corticosteroid, adapted to maternal–fetal transfer and potency of
the corticosteroid. The loss of effects after the 36 h infusions at 4
and 7 days gave us the first indication that there was a problem
with durability of ACS effects on the fetal lung (Fig. 4c).
Clinical information about durability of ACS has not been
carefully explored. The WHO reanalysis2 of the Roberts meta-
analysis found that for each benefit,6 the effective interval from
treatment to delivery differed (e.g. deaths decreased for intervals
<48 h only) while respiratory distress syndrom (RDS) decreased
from 48 h to 7 days but not after 7 days and IVH decreased only
for an interval >48 h. Liebowitz and Clyman39 reported increased
IVH for an interval from treatment of >10 days and Ring et al.40
reported an increase risk of ventilator support for fetuses exposed
to ACS at <28 weeks who delivered at >28 weeks. The long
intervals after ACS have not been considered as an important
variable in response and are difficult to study in clinical cohorts
unless there are time-matched control groups,19 but this question
can be studied with some precision in large animal models. The
biology about how a maturational signal to mature a fetal organ
which than can reverse to immaturity remains to be explained, but
is an important consideration for treatment strategies.
MINIMAL EXPOSURE FOR LUNG MATURATION IN MONKEYS
A parallel experiment in the pregnant Rhesus macaque using
ultrasound-guided fetal blood sampling demonstrated similar low
peak fetal blood betamethasone concentrations of about 5 ng/ml
for maternal doses of 0.125 mg/kg Beta Ac. This was as effective as
0.25 mg/kg of Beta P+ Beta Ac for fetal lung maturation and
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Fig. 4 Minimal dose and durability in sheep. a Constant betamethasone infusions in pregnant ewes to target fetal plasma levels of 20
(maternal infusions of Beta P loading dose 0.28 ng/kg then 0.48 ng/kg/12 h), 10 (loading dose of 0.14 ng/kg+ 0.24 ng/kg over 12 h), or 2 ng/ml
(loading dose of 0.028 ng Beta P+ 0.048 ng/kg/12 h infusion), with documentation of fetal levels of Beta for 24 h. b Evaluation of lung
performance by measuring VEI after infusion to the three target levels.7 c Additional data for fetuses infused with Beta P to achieve a fetal
exposure of 1 ng/ml for 36 h. There was no durable effect at 4 or 7 days. The clinical treatment requires two doses for durability in sheep.
Redrawn from ref. 7 d Ewes were treated with one or two doses of IM 0.25mg/kg Beta P plus Beta Ac. The lambs were delivered at intervals
from treatment of 1–10 days a single dose improved preterm lung function at 1 day but not 7 days. The two-dose treatments had efficacy to
7 days with residual effects at 10 days.
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blood concentrations of about 1 ng/ml at 48 h for a maturational
assessment at 5 days8 (Fig. 5c). Dosing monkeys with a lower dose
of 0.06 mg/kg Beta Ac did not induce lung maturation (Fig. 5b),
suggesting we have identified an effective low fetal concentration
of >1 ng/ml in fetal plasma.8
EFFECTS ON THE FETAL PRIMATE BRAIN
Transcriptome analysis of the fetal lung and brain after treatment
with ACS has provided insight on the pathways regulated by ACS
in these organs and potential side effects (Fig. 6). While 0.125 mg/
kg Beta Ac+ Beta P induced genes associated with lung cellular
differentiation and surfactant production, it also caused
suppression of lung morphogenesis pathways and induction of
apoptosis-related genes even after a short 5 h fetal exposure to
low-dose Beta Ac.12 In the fetal hippocampus ACS also had
unintended signaling consequences with suppression of neuronal
developmental pathways.12 These findings identify the pleiotropic
effects of ACS and potential toxicity of these drugs to fetal lung
and brain development.
ORAL DOSING WITH A CONTINUOUS EXPOSURE ABOVE THE
RESPONSE THRESHOLD IS NECESSARY
We have identified an approximate response threshold for fetal
plasma concentration of >1 ng/ml in sheep and monkeys and
a
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Fig. 6 Lung and hippocampus RNA-sequencing after treatment with ACS, studied 5 h after the ACS dose or saline control (n= 3 animals/
group). a Gene set enrichment analysis for biological processes associated with differentially regulated genes in the fetal lung 5 h after
treatment with Beta Ac evaluated 5 days after treatment. a ACS treatment induced cellular differentiation and surfactant-related processes as
well as apoptosis while suppressing immune response and lung developmental pathways. b Biological processes altered associated with
differentially regulated genes in the fetal hippocampus for 5 h after 0.125mg/kg Beta Ac+ Beta P resulted in suppression of genes associated






















































PO Dex-P 0.15 mg/kg Beta-Ac 0.125 mg/kg
IM Beta-Ac+Beta-P
0.25 mg/kg x2
PO Beta-P 0.15 mg/kg
x3 q12 h
PO Dex-P 0.15 mg/kg
x3 q12 h
PO Dex-P 0.15 mg/kg
x2 q24 h
IM Beta-Ac maternal
PO Dex-P 0.15 mg/kg - maternal





Beta-P+Beta-Ac 0.25 mg/kgPO Beta-P 0.15 mg/kg































































1 3 5 8
Time (h)
24
1 3 5 8
Time (h)
24
Fig. 5 Minimal corticosteroid dose for lung maturation in monkeys. a PK data for 0.125mg/kg Beta Ac maternal IM or 0.15 mg/kg oral Dex
P from nonpregnant monkeys. Redrawn from ref. 8 b Fetal monkeys at about 30 days gestational age were treated with maternal Beta Ac
given IM 0.125mg/kg and 5 days later were delivered for measurement of static pressure–volume curves (redrawn from ref. 12). c Sat
phosphotidylcholine in alveolar wash was also used as a maturation marker which increased with the low-dose Beta Ac treatment. d PK data
for 0.125mg/kg Beta Ac maternal IM or 0.15 mg/kg oral Dex P from monkey fetuses. The curves have only three data points because samples
from fetuses were collected with ultrasound-guided chordocentesis. The low dose of 0.125mg/kg yielded fetal plasma levels of about 1 ng/ml
for 24 h. equivalent to the much higher exposure with clinical dose (redrawn from ref. 12). e, f Fetal monkeys at about 30 days gestational age
were treated with maternal oral Beta P or Dex P and 5 days later were delivered for measurement of static pressure–volume curves. Redrawn
from refs. 8,12 *Different from control (p < 0.05).
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the inference of a similar value for the humans.33,35 That
threshold is easily achieved using the prolonged and contin-
uous exposure from Beta Ac with the two doses of the clinical
drug. The requirement for a continuous exposure above a
threshold for 48 h has not been formally tested by prospectively
designed experiments. However, in the monkey, 0.15 mg/kg of
oral Dex P given at 0 and 24 h intervals did not improve lung
gas volumes measured at 40 cm H2O pressure (V40).
8 Oral Beta P
given as 0.15 mg/kg as three doses at 12 h intervals did increase
V40 (Fig. 5e). These results in monkeys are consistent with
the need for a continuous exposure resulting from the longer
half-life of Beta than Dex in fetal plasma (Fig. 4e). Our
initial results with two doses of Beta P or Dex P in sheep also
indicate a continuous exposure is required for good matura-
tional responses.11 Our results with oral dosing in sheep further
indicate that continuous exposures for 48 h are required.13
SUMMARY
The PK information is of high resolution with the sheep and with
the Indian women because of the larger number of observations
that were possible and the ability to assess PD at intervals from 1
to 10 days after dosing in the sheep. We only evaluated the fetal
monkeys 5 days after treatment initiation. The results are
internally consistent for the two animal models. As the half-life
of betamethasone is twice as long as for dexamethasone, Beta P
can be dosed less frequently than Dex P to keep the concentration
above 1 ng/ml in the fetus. Oral and IM dosing PK information was
very similar for each treatment, when the oral dose was given to
the fasted women. The Beta P+ Beta Ac mixture had a very slow
clearance because of the delayed release of betamethasone from
the acetate prodrug. Of note, the one 3mg dose of Beta Ac used
for our measurements in humans was 25% that used clinically, and
betamethasone could be measured 2 weeks and would pre-
sumably be 4× higher with the two-dose clinical treatment
(12 mg) (Fig. 2).34 We view this persistence beyond the exposure
interval needed for lung maturation to be undesirable for mother
and fetus.
ACS AND PERSONALIZED MEDICINE
Personalized medicine is an attempt to selectively treat patients
who will benefit from the treatment and not be harmed by other
outcomes which are a risk from ACS. ACS in RCTs decrease RDS by
only 40%.2 The majority of women at risk of preterm delivery and
treated with ACS do not benefit from ACS, which means their
fetuses are unnecessarily exposed to corticosteroids. The benefits
for late preterm infants are modest as are benefits for elective C-
sections.26 A poorly documented number of women
have threatened preterm labor and are given ACS and deliver at
term with some clinical data suggesting adverse effects on fetal
growth and neurodevelopmental outcomes.21,37,41 There is also no
RCT data showing benefits for periviable deliveries prior to
24 weeks.19
Therefore, our approximate estimate is that 40–50% of all
deliveries in the US may receive ACS which benefit only a minority
of the pregnancies with a dose of ACS that is the wrong drug at
too high a dose.9 Fetal lung maturation-related biomarkers can be
measured using mRNA in amniotic fluid42 as can biomarkers for
gestation age in maternal blood.43 In the future, a test for fetal
lung maturity using maternal blood43 could allow the clinician to
only treat appropriate infants who would get RDS. Ideally, with
lower more appropriate doses, only fetuses who will benefit from
ACS will be exposed to ACS.
Such considerations may be more important in low resource
environments where many at risk patients may respond differently
and have different risks treatments with ACS may increase infant
mortality28 and corticosteroid induced hypoglycemia in the infant
may not be recognized and effectively treated.44 There is no dose
response information about ACS effects on other fetal organs. We
used lung function as it can be comparably measured across
species with studies. Dosing schedules to test low-dose strategies
have been reported.35,36 These low-dose strategies need to be
tested in randomized controlled trials.
Our conclusions are:
1. High fetal plasma levels do not contribute to the fetal lung
responses and are undesirable because of potential toxicity.
2. A threshold fetal plasma concentration for fetal maturation
is about 1 ng/ml for Beta or Dex for 48 h. The threshold
exposure of 1 ng/ml is an estimate made with some
precision using perfusion models (only for Beta P) and the
depo form of Beta Ac in sheep, and with less precision range
fetal plasma levels in monkeys, and estimates of exposures
in humans from cord blood.20,33,35 Results using oral dosing
also support this approximate value in sheep and monkeys.
Thus, the conclusion that standard treatment is using the
concentration of >1 ng/ml is adequate for lung maturation.
The current clinical dosing results in much higher concen-
trations.
3. The duration of exposure is critical for a durable response—
that duration of exposure is ≥48 h in the sheep. Clinical data
also support that duration of exposure is important for
clinical outcomes.2 The Beta Ac component of the clinical
drug will accomplish that, but two doses are required for a
durable response in sheep (Fig. 4). The downside of Beta Ac
is the prolonged maternal and fetal exposure if delivery
occurs at >48 h after treatment.
4. Oral or IM Dex P or Beta P will cause comparable lung
maturation if fetal exposures are comparable,8,13 based on
dosing to compensate for the PK differences in clearance of
the two drugs.
5. There seems to be no substantial difference in maturation
response with Dex or Beta so that either drug can be used
for ACS.17
6. Even the very low fetal exposures alter the transcriptome to
indicate potential adversity of the fetal lung and brain
within 5 h.12
GAPS IN KNOWLEDGE
Prove with an equivalency clinical trial that low-dose ACS (IM or
oral) are comparable to present standard treatments.
Test efficacy and risks of ACS with clinical studies in LMIC
environments.
Consider dosing based on maternal weight.
Understand where ACS signaling occurs in the fetal lung—to
possibly develop a treatment with less pleotropic effects for
antenatal treatments.
Develop new fetal evaluations that could be used to identify
fetuses that may benefit from ACS.
Explain the loss of durable lung maturation with time after
treatment.
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